📰 Solid Biosciences Inc News
Page 8 - Solid Biosciences Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Biosciences Inc. Real-time updates on events, politics, business and more.
October 16, 2022
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential viol
October 3, 2022
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
September 30, 2022
30.09.2022 - - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including ...
September 30, 2022
30.09.2022 - Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to ...
September 30, 2022
The combined company will focus on the advancement of neuromuscular and cardiac programs for the treatment of Duchenne muscular dystrophy.
June 13, 2022
Ovid Therapeutics (NASDAQ:OVID – Get Rating) and Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Ovid Therapeutics and Ultragenyx Pharmaceutical’s net […]
May 16, 2022
A number of firms have modified their ratings and price targets on shares of Solid Biosciences (NASDAQ: SLDB) recently: 5/3/2022 – Solid Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies […]
May 7, 2022
Equities analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Solid Biosciences […]
March 30, 2022
Equities research analysts expect that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.20) to ($0.17). Solid Biosciences posted earnings of ($0.19) per share during the same quarter […]